Bernardi Chiara, Garibotto Valentina, Mobashwera Behnaz, Negrin Robert S, Alam Israt S, Simonetta Federico
Division of Hematology, Department of Oncology, Geneva University Hospitals, Geneva, Switzerland.
Translational Research Center for Oncohematology, Department of Medicine, University of Geneva, Geneva, Switzerland.
J Nucl Med. 2024 Feb 15;65(3):357-61. doi: 10.2967/jnumed.123.266552.
Noninvasive molecular imaging of acute graft-versus-host disease (GvHD) after allogeneic hematopoietic stem cell transplantation has great potential to detect GvHD at the early stages, aid in grading of the disease, monitor treatment response, and guide therapeutic decisions. Although the specificity of currently available tracers appears insufficient for clinical GvHD diagnosis, recently, several preclinical studies have identified promising new imaging agents targeting one or more biologic processes involved in GvHD pathogenesis, ranging from T-cell activation to tissue damage. In this review, we summarize the different approaches reported to date for noninvasive detection of GvHD using molecular imaging with a specific focus on the use of PET. We discuss possible applications of molecular imaging for the detection of GvHD in the clinical setting, as well as some of the predictable challenges that are faced during clinical translation of these approaches.
异基因造血干细胞移植后急性移植物抗宿主病(GvHD)的无创分子成像在早期检测GvHD、辅助疾病分级、监测治疗反应以及指导治疗决策方面具有巨大潜力。尽管目前可用的示踪剂的特异性似乎不足以用于临床GvHD诊断,但最近,一些临床前研究已经确定了有前景的新型成像剂,这些成像剂靶向GvHD发病机制中涉及的一个或多个生物学过程,范围从T细胞激活到组织损伤。在本综述中,我们总结了迄今为止报道的使用分子成像无创检测GvHD的不同方法,特别关注PET的应用。我们讨论了分子成像在临床环境中检测GvHD的可能应用,以及这些方法在临床转化过程中面临的一些可预见的挑战。